Song Yuanbin, Chen Shuzhao, Liu Chenfei, Chen Lezong, Wang Weida, Wu Bingyi, Liang Yang
Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Front Pharmacol. 2023 Feb 17;14:1051305. doi: 10.3389/fphar.2023.1051305. eCollection 2023.
Maintenance therapy in adult T-cell acute lymphoblastic leukemia (T-ALL) is the longest phase but with limited option. The classic drugs used in the maintenance phase such as 6-mercaptopurine, methotrexate, corticosteroid and vincristine have potentially serious toxicities. Optimizing therapy in the modern age, chemo-free maintenance therapy regimens for patients with T-ALL may dramatically improve the maintenance therapeutic landscape. We report here the combination of Anti-programmed cell death protein 1 antibody and histone deacetylase inhibitor as chemo-free maintenance treatment in a T-ALL patient with literature review, thus providing a unique perspective in addition to valuable information which may inform novel therapeutic approaches.
成人T细胞急性淋巴细胞白血病（T-ALL）的维持治疗是最长的阶段，但选择有限。维持阶段使用的经典药物，如6-巯基嘌呤、甲氨蝶呤、皮质类固醇和长春新碱，具有潜在的严重毒性。在现代优化治疗中，T-ALL患者的无化疗维持治疗方案可能会显著改善维持治疗的局面。我们在此报告抗程序性细胞死亡蛋白1抗体和组蛋白去乙酰化酶抑制剂联合作为一名T-ALL患者的无化疗维持治疗，并进行文献综述，从而提供了一个独特的视角以及可能为新治疗方法提供参考的有价值信息。
